Justin Chen Li

Justin Chen Li is a seasoned executive with extensive experience in the biotech and investment sectors. Currently serving as the Chief Executive Officer of Helio Genomics since 2017, Justin focuses on utilizing AI and epigenomics to improve cancer treatment outcomes. In addition, Justin holds various leadership roles, including GM and VP of Finance & Business Development at the Terasaki Institute for Biomedical Innovation, and as a Venture Partner with SC Master Fund, where the emphasis is on investing in promising startups and VC firms in Southern California. Previously, Justin has made significant contributions at FactSet as a Consulting Manager, and at Phillips 66 as a Derivatives Market Analyst, among other roles. Justin holds an MBA in Healthcare from the University of California, Berkeley, Haas School of Business, and a Bachelor of Science in Finance from the University of Colorado.